Vaxart, Inc. (VXRT)
0.6297
+0.02
(+4.08%)
USD |
OTCM |
Apr 01, 16:00
Vaxart Research and Development Expense (TTM) : 201.58M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | 52.42M |
| Nuwellis, Inc. | 2.712M |
| Capricor Therapeutics, Inc. | 83.50M |
| Allogene Therapeutics, Inc. | 137.79M |
| Silvergate Capital Corp. | -- |